Huahua Zhong, Mingshi Gao, Shang Ma, Wenhan Zhang, Nachuan Cheng, Kexin Jiao, Bochen Zhu, Jie Song, Chong Yan, Dongyue Yue, Jianying Xi, Zunguo Du, Wenhua Zhu, Chongbo Zhao, Sushan Luo
{"title":"MyoPath: A deep learning pipeline for objective morphometric assessment of skeletal muscle biopsies","authors":"Huahua Zhong, Mingshi Gao, Shang Ma, Wenhan Zhang, Nachuan Cheng, Kexin Jiao, Bochen Zhu, Jie Song, Chong Yan, Dongyue Yue, Jianying Xi, Zunguo Du, Wenhua Zhu, Chongbo Zhao, Sushan Luo","doi":"10.1016/j.jpi.2026.100747","DOIUrl":"10.1016/j.jpi.2026.100747","url":null,"abstract":"<div><h3>Aims</h3><div>Muscle biopsy assessment relies on descriptive features that are difficult to compare across samples. We developed MyoPath to quantify these features and examined their usefulness in clinical biopsies and population-based autopsy material.</div></div><div><h3>Methods</h3><div>MyoPath combines Cellpose-SAM and conventional image analysis within QuPath to segment myofibers, fat, nuclei, and connective tissue. We analyzed 478 hematoxylin and eosin images from HuashanMuscle (79 snap-frozen biopsies) and GTEx (399 formalin-fixed, paraffin-embedded autopsy samples). Thirty-seven features were summarized by seven pathology indicators. A composite model trained on GTEx healthy and wasting strata was transferred to HuashanMuscle without retraining.</div></div><div><h3>Results</h3><div>Segmentation Dice coefficients ranged from 0.87 to 0.95 on annotated cryosections. Nuclear centralization index (NCI) and fiber size coefficient of variation (fiber CV) discriminated myopathy from controls in HuashanMuscle (AUC 0.85 and 0.79) and wasting from healthy donors in GTEx (0.74 and 0.74). Their GTEx associations changed little after age and sex adjustment. The composite achieved AUC 0.788 (95% CI 0.71–0.85) in GTEx and 0.873 (0.78–0.94) in HuashanMuscle. In the latter cohort, mean predicted probability was 0.49 compared with an observed myopathy proportion of 0.79.</div></div><div><h3>Conclusions</h3><div>NCI and fiber CV provide interpretable measures of muscle pathology in two distinct tissue settings. MyoPath supports quantitative comparison between groups; clinical severity grading and interpretation of absolute scores require further validation.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100747"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Parry, S. Jindal, T. Blackmur, P. Channathodiyil, E.-A. Raiber-Moreau, J. Lee, D. Mevorach, G. Mallel, R. Broderick, S. Ambrogio, M. Vecsler
{"title":"Demonstrating the accuracy and efficiency of artificial intelligence integrated workflows for primary breast cancer diagnosis: A comparative paired reader analysis","authors":"J. Parry, S. Jindal, T. Blackmur, P. Channathodiyil, E.-A. Raiber-Moreau, J. Lee, D. Mevorach, G. Mallel, R. Broderick, S. Ambrogio, M. Vecsler","doi":"10.1016/j.jpi.2026.100748","DOIUrl":"10.1016/j.jpi.2026.100748","url":null,"abstract":"<div><ul><li><span>•</span><span><div>AI-assisted digital pathology reduced mean review time by 43.5%.</div></span></li><li><span>•</span><span><div>AI-assisted workflow showed good usability; no observed increase in IHC use.</div></span></li><li><span>•</span><span><div>AI-enabled IHC pre-ordering could reduce TAT by ~2.5 days.</div></span></li><li><span>•</span><span><div>Diagnostic accuracy was maintained with AI assistance with 100% sensitivity.</div></span></li><li><span>•</span><span><div>The standalone AI showed high diagnostic accuracy, with AUC ≥0.99.</div></span></li></ul></div><div><div>Evidence on the real-world impact of artificial intelligence (AI) decision support on diagnostic efficiency and workflow outcomes in primary breast cancer pathology remains limited. This retrospective, single-site, paired reader, two-arm study evaluated the impact of AI-assisted digital pathology (DP + AI) versus standard DP on workflow efficiency and diagnostic performance in digitized consecutive breast biopsy cases. Primary endpoints were pathologist review time, lab turnaround time (TAT), and usability (survey-based). Secondary endpoints included diagnostic performance of pathologists across both arms and standalone AI against adjudicated reference standard. Analyses included descriptive statistics, paired <em>t</em>-test, and diagnostic performance metrics with 95% confidence intervals (CIs). The study included 194 digitized breast biopsies. The mean pathologist overall review time was reduced by 43.5% in DP + AI (40.18 [95% CI: 36.20–44.16] s) versus DP (71.12 [95% CI: 64.39–77.84] s) (<em>p</em> < 0.0001). Diagnostic agreement was 97.42% with DP and 99.48% with DP + AI, with 100% sensitivity observed in the DP + AI workflow. The standalone AI showed high diagnostic accuracy, with area under the curve values ≥0.99 across cancer subtypes. Usability survey showed high satisfaction, ease of use, and perceived clinical utility. Baseline TAT analysis of 3298 cases, independent of study cohort, showed longer TAT for cases requiring immunohistochemistry (IHC; 3.73 days) than for those not requiring (1.17 days). Retrospective workflow modelling suggested that AI-guided IHC pre-ordering could potentially reduce TAT by approximately 2.5 days for patients. DP + AI showed improvements in workflow efficiency while maintaining diagnostic performance. These findings suggest that integration of AI into routine breast pathology workflows may support faster diagnosis, optimized laboratory operations, and improved scalability.</div></div><div>Evidence on the real-world impact of artificial intelligence (AI) decision support on diagnostic efficiency and workflow outcomes in primary breast cancer pathology remains limited. This retrospective, single-site, paired reader, two-arm study evaluated the impact of AI-assisted digital pathology (DP + AI) versus standard DP on workflow efficiency and diagnostic performance in digitized consecutive breast biopsy cases. Prima","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100748"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Romina Battiato, Felipe Montoya Silva, Mylene Cabrera Morales, Deyana Salazar Romero, Martín H. Benites
{"title":"The accuracy–utility gap: Why AI accuracy does not guarantee clinical benefit in digital pathology","authors":"Romina Battiato, Felipe Montoya Silva, Mylene Cabrera Morales, Deyana Salazar Romero, Martín H. Benites","doi":"10.1016/j.jpi.2026.100751","DOIUrl":"10.1016/j.jpi.2026.100751","url":null,"abstract":"<div><div>Artificial intelligence (AI) in digital pathology has repeatedly achieved expert-level diagnostic accuracy under controlled validation conditions. However, its clinical translation—reflected in regulatory approval, routine adoption, changes in diagnostic decisions, or demonstrated patient benefit—remains inconsistent. This viewpoint argues that this discrepancy arises because diagnostic accuracy is a property of a model under specified conditions, whereas clinical utility emerges from the entire sociotechnical pathway in which the model is deployed. Building on recent work on standardization, system selection, institutional validation, and trial governance, we integrate these complementary layers into a continuous tissue-to-outcome pathway comprising six stages: tissue, image, model, workflow, decision, and outcome, with each stage explicitly linked to the claim it can support. Variability introduced at any stage may remain undetected and propagate downstream, potentially affecting clinical decisions and patient care. Accordingly, evidence generated at one stage cannot substitute for that required to support claims at subsequent stages. We therefore propose a stage-linked evidence map that identifies the principal risk and evidence required at each stage, while making explicit which stronger downstream claims remain unsupported. This framework enables reviewers and institutions considering adoption to identify where a study has addressed the accuracy–utility gap and where uncertainty remains. Evaluating AI across the complete pathway reframes the evidentiary requirements for clinical translation: high diagnostic accuracy is necessary, but insufficient, to establish meaningful clinical utility.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100751"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spatial characterization of prostate cancer microenvironment with DRAQ5&Eosin fluorescence imaging and quantitative feature identification","authors":"Michail Georgios Papachristos, Emiliano Spezi, Carolina Fuentes, Rachel J. Errington, Dimitris Parthimos","doi":"10.1016/j.jpi.2026.100746","DOIUrl":"10.1016/j.jpi.2026.100746","url":null,"abstract":"<div><div>Prostate cancer progression is routinely quantified by expert pathologists on hematoxylin and eosin (H&E)-stained tissue using Gleason grading. However, tissue processing for H&E staining is very time-consuming, whereas Gleason grading is often subject to inter- and intraobserver variability. This diagnostic variability can be reduced through utilization of mathematically quantitative and standardized metrics to analyze the prostatic tissue microenvironment. In this study, we identify an optimal set of metrics that could potentially be used as a diagnostic biomarker signature, through a combination of tissue architectures and gradient boosting algorithms. We employed fluorescence microscopy imaged prostatic tissue, stained with DRAQ5&Eosin, which allows for rapid real-time staining and imaging of the tissue, as opposed to H&E, and also provides high-resolution nuclear and cytoplasmic images. We then used engineered algorithmic pipelines to extract intensity-based, morphological, and textural features from four different tissue components: epithelial nuclei, epithelial cytoplasm, stromal nuclei, and stromal cytoplasm. We developed classification models to distinguish healthy from cancerous prostatic regions based on the extracted features and identified the most predictive features. Our epithelial-based models achieved area under the curves (AUCs) in the range 0.646–0.896, whereas our stromal-based models attained AUCs in the range 0.742–0.840. Our DRAQ5&Eosin-based models were thus able to identify important tissue specific spatial biomarkers, allowing for the creation of nuclear and cytoplasmic spatial profiles for healthy and cancerous prostatic tissue respectively.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100746"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tumor-area mitosis proportion as an image-derived mitotic phenotype in lung squamous cell carcinoma: Patient-level prognostic and multi-omics evaluation","authors":"Gulcin Yilmaz Gunes, Mehmet Akif Cifci","doi":"10.1016/j.jpi.2026.100750","DOIUrl":"10.1016/j.jpi.2026.100750","url":null,"abstract":"<div><h3>Background</h3><div>Mitotic activity is a recognized marker of tumor proliferation, yet its reproducible assessment across whole-slide images (WSIs) remains difficult. We developed a transfer-learning framework for lung squamous cell carcinoma (LUSC) and evaluated whether a patch-derived tumor-area mitosis proportion (TAMP) was associated with survival and molecular tumor characteristics.</div></div><div><h3>Methods</h3><div>The analysis combined MIDOG 2022 with TCGA-LUSC, including 478 patients and 512 diagnostic WSIs after quality control. Tumor regions and mitotic figures were reviewed by two pathologists with interobserver agreement of Cohen's κ ≥ 0.85. A ResNet-50 model was trained on MIDOG and subsequently adapted to TCGA-LUSC using Focal Loss and stain-aware augmentation. Target-domain performance was evaluated using patient-level stratified 5-fold cross-validation and an additional WSI-level holdout analysis to address potential leakage from the initial patch-level partitioning. TAMP was calculated from patient-level out-of-fold predictions as the proportion of evaluable tumor patches classified as mitosis-positive. Associations with overall survival, immune and genomic features, transcriptomic programs, predicted drug response, and transcription-factor activity were subsequently examined. Multivariable Cox regression adjusted for age, sex, smoking status, tumor stage, and Eastern Cooperative Oncology Group performance status.</div></div><div><h3>Results</h3><div>The model achieved an area under the receiver operating characteristic curve (AUC) of 0.975 (95% confidence interval (CI): 0.965–0.980) on the held-out MIDOG test set. In TCGA-LUSC, fine-tuning increased the initial patch-level AUC from 0.82 to 0.92. Patient-level cross-validation yielded a mean AUC of 0.89 (95% CI: 0.86–0.90), and WSI-level holdout validation yielded an AUC of 0.90 (95% CI: 0.84–0.90). High TAMP was associated with poorer overall survival (log-rank <em>p</em> = 0.008; HR = 1.82, 95% CI: 1.18–2.81) and remained associated with mortality after multivariable adjustment (adjusted HR = 1.68, 95% CI: 1.08–2.62; <em>p</em> = 0.022). Higher TAMP was also associated with lower stromal fraction, selected immune-cell differences, greater indel-derived neoantigen load and indel burden, and enrichment of stem-cell proliferation, growth-factor-response, E2F-target, G2M-checkpoint, and MYC-target programs. Additional associations were observed with predicted sensitivity to selected cell-cycle-targeting compounds and with proliferation-related transcription-factor activity.</div></div><div><h3>Conclusions</h3><div>TAMP provides a patient-level, image-derived representation of mitosis-positive tumor regions that was associated with survival and several molecular features in TCGA-LUSC. Its association with overall survival persisted after adjustment for major clinical covariates. External multicenter validation, prespecified threshold evaluation, and prospective assessme","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100750"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence in digital pathology: Principles, applications, challenges, and future directions","authors":"Yifei Wang, Leona Odabachian","doi":"10.1016/j.jpi.2026.100749","DOIUrl":"10.1016/j.jpi.2026.100749","url":null,"abstract":"<div><div>This article provides an overview of digital pathology and its evolving role in modern diagnostic practice. We begin by comparing conventional microscopy with digital pathology and outlining the major components of the digital pathology workflow. We then explore whole-slide imaging, its imaging modalities, scanner technologies, image storage, and image management systems. We then examine the role of artificial intelligence (AI) in digital pathology, discussing current AI applications and the spectrum of computational approaches, from conventional feature-engineering methods to deep learning and multimodal models. Finally, we review the clinical applications of digital pathology, summarize its implementation across US medical centers, and discuss the technical, regulatory, and operational challenges that must be addressed for broader clinical adoption.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of a novel “gross room” device to increase lymph node yield in colorectal cancer specimens","authors":"Kadir Isidan, Hussein Alnajar, Monika Krezalek, Zitlali Montiel-Martinez, Alicia Huber, John Groth","doi":"10.1016/j.jpi.2026.100745","DOIUrl":"10.1016/j.jpi.2026.100745","url":null,"abstract":"<div><div>Nodal staging plays a vital role in pathological staging of colorectal cancer (CRC). According to AJCC guidelines, at least 12 lymph nodes are required for nodal staging. However, many previous studies have shown the importance of retrieving as many lymph nodes as possible. In this study, we evaluated an optical imaging-based device (Cision InVision) to increase lymph node yield in CRC specimens. The device utilizes infrared light to differentiate lymphoid tissue from other tissue. We recruited 31 colorectal resections. A senior resident or pathologist's assistant conventionally grossed the recruited specimens. Thereafter, the remaining fatty tissue was scanned with the device to identify additional lymph nodes. Overall, the device increased the lymph node numbers, with an average increase of 48%. This increase was particularly notable for smaller lymph nodes (<3 mm). In the entire study, a total of 1422 lymph nodes were harvested, including 33 positive lymph nodes from 10 nodal-positive cases. Conventional grossing retrieved 29 positive lymph nodes, whereas the device retrieved 4 additional positive nodes, resulting in two upstaged patients. Among these two patients, one patient was upstaged from node-negative to node-positive disease. In this “proof-of-concept” study with a limited number of subjects, our findings demonstrate that the Cision InVision device increases lymph node yield, especially for smaller nodes, leading to stage changes in 2 out of 31 patients, with one case upstaged from node-negative to node-positive disease. Whereas further research with larger cohorts is needed to address the limitations and explore broader clinical implications, our findings preliminarily highlight its probable value in CRC lymph node assessment.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"23 ","pages":"Article 100745"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149348025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin Adjadj, Pierre-Antoine Bannier, Guillaume Horent, Sebastien Mandela, Gary Klajer, Aurore Lyon, Kathryn Schutte, Ulysse Marteau, Valentin Gaury, Laura Dumont, Thomas Mathieu, Reda Belbahri, Benoît Schmauch, Eric Durand, Katharina Von Loga, Lucie Gillet
{"title":"Toward comprehensive cellular characterization of H&E slides","authors":"Benjamin Adjadj, Pierre-Antoine Bannier, Guillaume Horent, Sebastien Mandela, Gary Klajer, Aurore Lyon, Kathryn Schutte, Ulysse Marteau, Valentin Gaury, Laura Dumont, Thomas Mathieu, Reda Belbahri, Benoît Schmauch, Eric Durand, Katharina Von Loga, Lucie Gillet","doi":"10.1016/j.jpi.2026.100696","DOIUrl":"10.1016/j.jpi.2026.100696","url":null,"abstract":"<div><div>Cell detection, segmentation, and classification are essential for analyzing tumor microenvironments (TME) on hematoxylin and eosin (H&E) slides. Existing methods suffer from poor performance on understudied cell types (rare or not present in public datasets) and limited cross-domain generalization. To address these shortcomings, we introduce HistoPLUS, a state-of-the-art model for cell analysis, trained on a novel curated pan-cancer dataset of 108,722 nuclei covering 13 cell types. In external validation across 4 independent cohorts, HistoPLUS outperforms current state-of-the-art models in detection quality by 5.2% and overall F1 classification score by 23.7%, while using 5× fewer parameters. In addition, we show that HistoPLUS robustly transfers to two oncology indications unseen during training and allows interpretable biomarker discovery in downstream tasks, outperforming clinical baselines and prior deep learning methods. To support broader TME biomarker research, we release the model weights and inference code.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"22 ","pages":"Article 100696"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148730159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatemeh Zabihollahy, Cheuk-To Jeremy Yu, David W. Dodington, George M. Yousef
{"title":"CurvReg: Curvature-aware registration for multi-stain alignment of liver biopsies","authors":"Fatemeh Zabihollahy, Cheuk-To Jeremy Yu, David W. Dodington, George M. Yousef","doi":"10.1016/j.jpi.2026.100698","DOIUrl":"10.1016/j.jpi.2026.100698","url":null,"abstract":"<div><div>Accurate alignment of multi-stain liver biopsy whole-slide images is critical for emerging computational pathology workflows, yet remains challenging due to curved biopsy geometry, non-rigid distortions, and substantial stain-dependent appearance variation. We introduce CurvReg, a curvature-aware, stain-independent registration framework designed to address these challenges by decomposing each biopsy into anatomically coherent segments for piecewise affine alignment, followed by deep learning-based deformable refinement operating directly on tissue segmentation masks rather than raw stained images. By estimating deformation from structural geometry rather than stain intensities, CurvReg enforces anatomically plausible warps and substantially improves robustness to staining, imaging, and device variability. We evaluated CurvReg across three multi-stain liver biopsy datasets and an independent public kidney biopsy dataset from the ANHIR challenge. On the internal multi-stain dataset (Dataset #1) containing hematoxylin–eosin (H&E), Masson's trichrome (MT), and CK7 sections with bile duct annotations, pre-registration mean target registration error (TRE) measured 231.5 μm (H&E–MT), 255.3 μm (MT–CK7), and 188.7 μm (H&E–CK7). After registration, TRE decreased to 51.9 μm, 57.9 μm, and 50.9 μm, respectively, with a >70% reduction across all stain pairs (<em>p</em> < 0.001). Dice similarity increased from 0.54–0.60 to 0.95 (H&E–MT), 0.95 (MT–CK7), and 0.96 (H&E–CK7) (<em>p</em> < 0.001). On the internal portal tract and hepatic vein-annotated H&E–MT dataset (Dataset #2), TRE improved from 147.9 to 48.0 μm (corresponding to a 67.5% reduction; <em>p</em> < 0.001) and Dice from 0.76 to 0.98 (<em>p</em> < 0.001). External validation on a heterogeneous multi-center H&E–MT dataset showed similar gains, with TRE reduced from 93.4 to 42.2 μm (>50% reduction; <em>p</em> < 0.001) and Dice increasing from 0.61 to 0.95 (<em>p</em> < 0.001), confirming robust generalization across scanners, staining protocols, and tissue processing variations. Evaluation on the independent ANHIR kidney biopsy dataset (PAS–MT sections) further demonstrated the generalizability of CurvReg to a different tissue type and stain combination, reducing TRE from 107.2 to 81.6 μm (<em>p</em> = 0.024) while improving Dice similarity from 0.90 to 0.97 (<em>p</em> < 0.001). To highlight downstream clinical value, we demonstrate that MT-derived portal tract and hepatic vein segmentations can be accurately transferred onto H&E using CurvReg, enabling consistent vascular delineation within the diagnostic stain.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"22 ","pages":"Article 100698"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148854391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Albert G. Siebers, Quirinus J.M. Voorham, Chantal C.H.J. Kuijpers, Annette H. Bruggink, Paul A. Seegers, Esther C. van den Broek, Menno Hoogeveen, Michiel van den Brand, Carolien H.M. van Deurzen, Robby E. Kibbelaar
{"title":"The Dutch Nationwide Pathology Databank and its central role in health research","authors":"Albert G. Siebers, Quirinus J.M. Voorham, Chantal C.H.J. Kuijpers, Annette H. Bruggink, Paul A. Seegers, Esther C. van den Broek, Menno Hoogeveen, Michiel van den Brand, Carolien H.M. van Deurzen, Robby E. Kibbelaar","doi":"10.1016/j.jpi.2026.100695","DOIUrl":"10.1016/j.jpi.2026.100695","url":null,"abstract":"<div><div>The Dutch Nationwide Pathology Databank (Palga) was established in 1971 and achieved nationwide coverage of all Dutch pathology departments in 1991. It serves as the central repository for pathology data across the Netherlands. Palga manages a nationwide IT infrastructure enabling the collection, structuring, and secure sharing of pathology data from all Dutch pathology departments. This unique infrastructure supports diagnostics in patient care by enabling pathologists to access nationwide patient pathology histories and by supporting standardized, structured reporting, particularly in population-based screening programs and oncological pathology. It also serves as a valuable resource for secondary data use, supporting scientific research and healthcare policy decision-making.</div><div>This article provides an overview of the Palga infrastructure, with a focus on its embedded scientific database for secondary use. It describes how pathology data are collected, structured, and shared, and explains how data are securely processed in compliance with current legislation, with particular emphasis on safe secondary use.</div><div>Secure secondary use of pathology data is expected to increasingly advance evidence-based healthcare research for the benefit of society. Palga's nationwide infrastructure provides substantial added value for patient care, health research, and healthcare quality improvement, while enabling responsible and socially valuable secondary data use through collaboration and robust legal and ethical governance.</div></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"22 ","pages":"Article 100695"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}